

**FOR IMMEDIATE RELEASE
NOVEMBER 24, 2005**

**CONTACT: Gemma Saccomanni
Tel. +3906-5913012/4
Francesca Marchi
Tel. +3906-5913012/4**

**ELI LILLY AND COMPANY DELIVERS URGENT HEALTH MESSAGE TO
6TH WORLD SUMMIT OF NOBEL PEACE LAUREATES**

November 24, 2005 (Rome, Italy)—Gino Santini, a senior vice president at Eli Lilly and Company, addressed the audience at this year's World Summit of Nobel Peace Laureates—driving home the message about the importance of fighting a deadly disease still unknown to many.

Multi-drug-resistant tuberculosis (MDR-TB), a type of tuberculosis caused by incomplete treatment of regular TB, is a growing global pandemic—there are an estimated 400,000 new cases of MDR-TB every year. MDR-TB spreads from person to person as easily as regular TB. Only a handful of drugs, of which Lilly makes two, cure MDR-TB, and patients must take these antibiotics uninterrupted for up to two years.

To stop this disease before it spirals out of control, Eli Lilly and Company launched the Lilly MDR-TB Partnership in 2003—a \$70 million multi-pronged initiative to fight MDR-TB. Just two years later, Lilly already has 13 partners in this fight, including major international public health organizations and four pharmaceutical companies in countries with some of the highest MDR-TB burdens.

As part of its philanthropic effort, Lilly provides manufacturing technology, training, and expertise for its two MDR-TB drugs to four companies in countries that need them most. One of these “transfer of technology” partners, Aspen Pharmicare in South Africa, has just sold its first batch of cycloserine, a Lilly MDR-TB antibiotic.

Lilly is delighted to welcome its newest transfer of technology partner, SIA International in Russia. SIA has 47 branches across Russia and delivers drugs to two thirds of the country's pharmacies. Once in gear, SIA will produce both of Lilly's MDR-TB drugs.

For more information about the Lilly MDR-TB partnership, visit our Website at www.lillyMDR-TB.com.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

#

Seromycin® and Capastat® are registered trademarks of Eli Lilly and Company